Function of the transforming growth factor-β1/c-Jun N-terminal kinase signaling pathway in the action of thalidomide on a rat model of pulmonary fibrosis

Experimental and Therapeutic Medicine

Volumn 7, Issue 3, 2014, Pages 669-674

  Liu, Xuejun ^a   Qian, Li ^a   Nan, Haoyu ^a   Cui, Miao ^a   Hao, Xiaoyan ^a   Du, Yufeng ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

smooth muscle actin; c Jun N terminal kinase; Pulmonary fibrosis; Thalidomide

Indexed keywords

EID: 84892982995     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1457     Document Type: Article

References (23)

1. Collard HR and Pantilat SZ: Dyspnea in interstitial lung disease. Curr Opin Support Palliat Care 2: 100-104, 2008.
2. Hou N, Torii S, Saito N, Hosaka M and Takeuchi T: Reactive oxygen species-mediated pancreatic beta-cell death is regulated by interactions between stress-activated protein kinases, p38 and c-Jun N-terminal kinase, and mitogen-activated protein kinase phosphatases. Endocrinology 149: 1654-1665, 2008.
3. Horton MR, Santopietro V, Mathew L, et al: Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 157: 398-406, 2012.
4. Smith JL, Schaffner AE, Hofmeister JK, et al: ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice. Mol Cell Biol 20: 8026-8034, 2000.
5. Choe JY, Jung HJ, Park KY, et al: Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 59: 177-188, 2010.
6. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
7. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675-1680, 1993.
8. Koch HP: Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 22: 165-242, 1985.
9. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S and Horie T: Transforming growth Factor-betal induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 163: 152-157, 2001.
10. Alcorn JF, Guala AS, van der Velden J, et al: Jun N-terminal kinase1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1. J Cell Sci 121: 1036-1045, 2008.
11. Kapoun AM, Gaspar NJ, Wang Y, et al: Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGF betaRI-induced myofibroblast differentiation and profibrotic gene expression. Mol Pharmacol 70: 518-531, 2006.
12. Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ and Barr RK: Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 1697: 89-101, 2004.
13. Liu J and Lin A: Role of JNK activation apoptosis: a double-edged sword. Cell Res 15: 36-42, 2005.
14. Bennett BL, Sasaki DT, Murray BW, et al: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98: 13681-13686, 2001.
15. Zhang C-X and Liu X-J: The expression and significance of p-JNK protein and α-SMA in rats with pulmonary fibrosis. Chinese Remedies & Clinics 12: 36-38, 2012 (In Chinese).
16. Joglekar S and Levin M: The promise of thalidomide: evolving indications. Drugs Today (Barc) 40: 197-204, 2004.
17. Arai H, Furusu A, Nishino T, et al: Thalidomide prevents the progression of peritoneal fibrosis in mice. Acta Histochem Cytochem 44: 51-60, 2011.
18. Chong LW, Hsu YC, Chiu YT, Yang KC and Huang YT: Anti-fibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci 13: 403-418, 2006.
19. Ye Q, Chen B, Tong Z, et al: Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 28: 824-831, 2006.
20. Liu X, Qian L, Nan H, et al: Thalidomide inhibits the over-expression of type I collagen in pulmonary fibrosis rats via inhibition the JNK signaling pathway. Chinese Journal of Geriatrics (In Press).
21. Luo X and Liu X-J: Thalidomide suppresses bleomycin-induced pulmonary fibrosis by down-regulating expressions of TGF-β1 and TNF-α in rats. Chinese Remedies & Clinics 10: 1346-1349, 2010 (In Chinese).
22. Horton MR and Hallowell RW: Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis. Drugs Today (Barc) 48: 661-671, 2012.
23. Horton MR, Santopietro V, Mathew L, et al: Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 157: 398-406, 2012.